Rethinking Vitamin D Deficiency: Controversies and Practical Guidance for Clinical Management
Authors:
- Manuel Sosa-HenríquezMSManuel Sosa-Henríquez
- Óscar Torregrosa-SuauÓTÓscar Torregrosa-Suau
- María Jesús Gómez de Tejada-RomeroMTMaría Jesús Gómez de Tejada-Romero
- María Jesús Cancelo-HidalgoMCMaría Jesús Cancelo-Hidalgo
- Francisco José Tarazona-SantabalbinaFTFrancisco José Tarazona-Santabalbina
- Iñigo Etxebarria-ForondaIEIñigo Etxebarria-Foronda
- Guillermo Martínez Díaz-GuerraGDGuillermo Martínez Díaz-Guerra
- Carmen Valdés-LlorcaCVCarmen Valdés-Llorca
Open Access
Abstract
Vitamin D (VD), due to its hormonal action, plays a crucial role in calcium homeostasis and bone metabolism, and its deficiency has been associated with musculoskeletal disorders such as osteoporosis, fractures, and osteomalacia, as well as a growing attention of chronic conditions and certain cancers. Despite its physiological relevance and widespread prevalence, particularly among older individuals, patients with chronic diseases, institutionalized populations and pregnant or lactating women, clinical approaches to diagnosing and managing vitamin D deficiency (VDD) remain heterogeneous across guidelines and healthcare settings. This reflects a lack of consensus regarding the benefits and limitations of universal versus selective screening, the definition of adequate serum concentrations, and the clinical indications for supplementation across different patient profiles. This narrative review explores key controversies in the clinical management of VDD, including current perspectives on screening strategies and target populations, indications for empirical supplementation, criteria for biochemical monitoring, and therapeutic goals in bone-related outcomes. In particular, the review discusses the rationale for adopting a 30 ng/mL (75 nmol/L) threshold for adequate serum 25(OH) concentrations in skeletal health, the role of vitamin D and calcium in osteoporosis treatment, and the pharmacological advantages of cholecalciferol compared to other vitamin D compounds. Through a synthesis of available evidence and expert consensus, the review aims to support clinical decision-making in the prevention and treatment of VDD and to identify areas that require further clarification or research. This review aims to support evidence-based clinical decision-making.Keywords
All Related Versions
This publication has 156 references indexed in Scilit:
- Vitamin D supplementation and risk of falling: outcomes from the randomized, placebo‐controlled D‐Health TrialJournal of Cachexia, Sarcopenia and Muscle, 2021
- Screening for Vitamin D Deficiency in AdultsJAMA, 2021
- The USPSTF 2021 Recommendations on Screening for Asymptomatic Vitamin D Deficiency in AdultsJAMA, 2021
- Screening for Vitamin D Deficiency in AdultsJAMA, 2021
- Vitamin D supplementation for women during pregnancyCochrane Database of Systematic Reviews, 2019
- Monthly High-Dose Vitamin D Treatment for the Prevention of Functional DeclineJAMA Internal Medicine, 2016
- Standardizing Vitamin D Assays: The Way ForwardJournal of Bone and Mineral Research, 2014
- Oral supplementation with 25(OH)D3 versus vitamin D3: Effects on 25(OH)D levels, lower extremity function, blood pressure, and markers of innate immunityJournal of Bone and Mineral Research, 2011
- Annual High-Dose Oral Vitamin D and Falls and Fractures in Older WomenJAMA, 2010
- Efficacy of different doses and time intervals of oral vitamin D supplementation with or without calcium in elderly nursing home residentsOsteoporosis International, 2007